Incorporating immunotherapy into stage 3 non-small cell lung cancer regimens increases surgical success rates and substantially reduces postoperative recurrence.
Multidisciplinary evaluation extends targeted therapies and immunotherapies to patients who were previously considered unsuitable candidates for surgical resection.
Careful assessment of patient clinical traits and predictive biomarkers remains critical to balance severe adverse effects against curative surgical opportunities.